Roivant Sciences (ROIV) Income from Non-Controlling Interests (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Income from Non-Controlling Interests came in at -$150.9 million in Q4 2025, down 8.67% YoY from -$165.2 million in Q4 2024, and down 187.29% on a QoQ basis from -$52.5 million in Q3 2025.
Roivant Sciences (ROIV) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Income from Non-Controlling Interests data on file, last reported at -$150.9 million in Q4 2025.
- Quarterly Income from Non-Controlling Interests fell 8.67% year-over-year to -$150.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$392.8 million (down 25.6% YoY) and the FY2026 annual result came in at -$98.1 million, up 46.88% from the prior year.
- Income from Non-Controlling Interests eased to -$150.9 million in Q4 2025, from -$52.5 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$17.2 million in Q3 2021 to a low of -$150.9 million in Q4 2025.
- A 5-year average of -$56.6 million and a median of -$49.7 million in 2024 frame the typical range for Income from Non-Controlling Interests.
- The widest YoY moves for Income from Non-Controlling Interests: up 5.2% in 2021, down 299.13% in 2021.
- Tracing ROIV's Income from Non-Controlling Interests over 5 years: stood at -$57.6 million in 2021, then plunged by 37.47% to -$79.2 million in 2022, then dropped by 9.03% to -$86.3 million in 2023, then tumbled by 60.82% to -$138.9 million in 2024, then declined by 8.67% to -$150.9 million in 2025.
- The last three Income from Non-Controlling Interests figures came in at -$150.9 million (Q4 2025), -$52.5 million (Q3 2025), and -$50.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | -100.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -100.77 Mn |
| Dec 31, 2025 | -150.89 Mn |
| Sep 30, 2025 | -52.52 Mn |
| Jun 30, 2025 | -50.56 Mn |
| Dec 31, 2024 | -138.85 Mn |
| Sep 30, 2024 | -49.74 Mn |
| Jun 30, 2024 | -37.81 Mn |
| Dec 31, 2023 | -86.34 Mn |
| Sep 30, 2023 | -26.79 Mn |
| Jun 30, 2023 | -36.03 Mn |
| Dec 31, 2022 | -79.19 Mn |
| Sep 30, 2022 | -24.33 Mn |
| Jun 30, 2022 | -21.98 Mn |
| Dec 31, 2021 | -57.60 Mn |
| Sep 30, 2021 | -17.16 Mn |
| Jun 30, 2021 | -18.90 Mn |
| Dec 31, 2020 | -14.57 Mn |
| Sep 30, 2020 | -18.10 Mn |
| Jun 30, 2020 | -4.73 Mn |